Search
Methocarbamol
go.drugbank.com/drugs/DB00423ApprovedInvestigationalVet approved[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts … [L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265]
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalIt was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Lamivudine
go.drugbank.com/drugs/DB00709ApprovedInvestigationalIt is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Mixtures: Symfi Lo, Symfi LoCysteine
go.drugbank.com/drugs/DB00151ApprovedInvestigationalNutraceuticalA thiol-containing non-essential amino acid that is oxidized to form cystine.
Magnesium silicate
go.drugbank.com/drugs/DB13249ApprovedWithdrawn[L2603] Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.[L2605]
Fentanyl
go.drugbank.com/drugs/DB00813ApprovedIllicitInvestigationalVet approvedFentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. … [A179542] Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: FENTANYL ACTAVIS 25UG/H T, FENTANYL ACTAVIS 50UG/H TOfatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[A6921] Ofatumumab was first approved by the FDA in 2009. … [L12612] Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Medroxyprogesterone acetate
go.drugbank.com/drugs/DB00603ApprovedInvestigationalMedroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. … [A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy,
Avutometinib
go.drugbank.com/drugs/DB15254ApprovedInvestigational[A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer
Mixtures: Avmapki Fakzynja Co-packSynonyms: RO-5126766 free base